tirzepatide mace What Is Used for? Approved and Potential Uses An Observational Study of Cardiovascular

Learn whats required for GLP-1 weight loss programsget started today.

Pfizers dose-optimization studies of once-daily formulations of danuglipron ( NCT06567327 and NCT06568731 ) met key pharmacokinetic objectives and confirmed a formulation and dose with the potential to deliver a competitive efficacy and tolerability profile in Phase 3 testing, based on earlier studies of twice-daily danuglipron

So, which patients should clinicians actually be screening

You've all heard by now about a new class of weight loss medications: GLP-1 receptor agonists

These findings support its potential as a scalable, population-level cardiometabolic intervention and highlight the need for system-level strategies to enhance access and uptake.